ACS (including myocardial infarction with or without ST elevation, unstable angina).
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: 180 mg bempedoic acid tablet daily along with high-dose atorvastatin (40-80 mg) daily from the time of acute coronary syndrome diagnosis until t
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age = 18 years Confirmed diagnosis of acute coronary syndrome LDL-C level = 70 mg/dL within the first 24 hours of patient admission Ability and willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: History of hypersensitivity or allergy to bempedoic acid or statins Kidney failure with creatinine clearance less than 30 ml/min History of severe statin-related myopathy leading to discontinuation of the drug Known history of gout or hyperuricemia (uric acid > 9 mg/dl) Pregnancy or breastfeeding Presence of cardiogenic shock upon admission? Life-threatening arrhythmias Patients with a life expectancy of less than 6 months, according to the treating physician's clinical judgment History of heart surgery in the past 3 months Known severe valvular heart disease Unwillingness or inability to cooperate for follow-up visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of achieving LDL-C levels below 55 mg/dL between the intervention and control groups at the end of the study. Timepoint: week 8. Method of measurement: Blood test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the percentage reduction in LDL-C to below 55 mg/dL. Timepoint: Baseline and during the study. Method of measurement: lab test.;Comparison of the percentage reduction and changes in LDL-C in the two intervention groups. Timepoint: In weeks 4 and 8. Method of measurement: lab test.;? Reduction in the occurrence of major cardiovascular events (MACE), including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. Timepoint: Over 8 weeks. Method of measurement: lab test.;Reduction of high-sensitivity C-reactive protein. Timepoint: Baseline and at 4 and 8 weeks. Method of measurement: lab test.;Troponin. Timepoint: baseline and pre-discharge. Method of measurement: lab test.;?Occurrence of drug side effects, especially muscular side effects (including cramps, myopathy), rhabdomyolysis. Timepoint: ?At 4 and 8 weeks. Method of measurement: lab test.;Uric Acid. Timepoint: ?At 4 and 8 weeks. Method of measurement: Lab test.;Liver enzymes. Timepoint: ?At 4 and 8 weeks. Method of measurement: Lab test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKeyhan Mohammadi
Tehran University of Medical Sciences
Outcome results
None listed